BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  FDA Accepts Bayer’s Application to Expand Nubeqa into New Prostate Cancer Indication

  The FDA accepted Bayer’s supplemental New Drug Application for its proposed oral treatment for metastatic hormone-sensitive prostate cancer.

  May 4, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  COVID-19 May Worsen Childhood Asthma and 3rd mRNA Shot May Not Suffice

  New studies suggest that the virus may aggravate childhood asthma after infection. For that and more COVID-19 news, continue reading.

  May 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Compass, Astrazeneca Move Forward in Biliary Tract Cancer Treatments

  Compass and AstraZeneca have both provided updates to their clinical therapeutic programs focused on biliary tract cancers.

  May 4, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Global Roundup: FDA Hits Junshi, HUTCHMED with Complete Response Letters

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  May 4, 2022

   · 

  7 min read

   · 

  Alex Keown
• 

  Business

  Awakn’s Anthony Tennyson on Providing Hope for Those Suffering from Addiction

  Awakn researches and develops drug-assisted psychotherapy treatments, focusing on psychedelic drugs to treat addiction.

  May 4, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Business

  Jazz Adds Narcolepsy Pact with Sumitomo, Sees Clear Ahead to Vision 2025

  Jazz’s Q1 included a key licensing deal with Werewolf Therapeutics and another announced Wednesday with Japan’s Sumitomo Pharma Co. for a narcolepsy treatment.

  May 4, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Money on the Move: April Showers Bring May Flowers—and Funding

  Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading.

  May 4, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Novartis’ Kisqali Adds Years to Breast Cancer Patients’ Lives

  Novartis’ Kisqali (ribociclib) plus the chemotherapy drug fulvestrant provided some post-menopausal breast cancer patients’ survival benefit of more than five-and-a-half years of life.

  May 4, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Weigh to Go: Gelesis Boasts Positive Results for Weight Loss Treatment

  PureTech Health announced its founded entity, Gelesis Holdings, presented positive results from the Light-Up clinical trial of GS200 in overweight and obese adults who have prediabetes or type 2 diabetes.

  May 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Regeneron Overcomes Loss of COVID Antibody to Post Positive First Quarter

  Despite the loss of its COVID-19 antibody, REGEN-COV, earlier this year, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.

  May 4, 2022

   · 

  3 min read

   · 

  Alex Keown